News: Corporate

10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).

Read more…

31 July 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark office (USPTO) has completed its examination of the Company’s patent application (14/379,239), entitled: “Phenotype profile of human retinal progenitor cells” and has issued a notification of allowance for the issuance of a patent.

Read more…

Further long-term data demonstrate continuing, clinically meaningful efficacy at all time-points measured out to 18 months post-treatment

29 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP).  RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and ultimately blindness.

Read more…

25 June 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.

Read more…

17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.

Read more…

Newly published positive efficacy data in an accepted model of Huntington’s disease

07 May 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled “Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington’s disease”.

Read more…

6 December 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2019.

Read more…

To log on to view a recording of the analyst presentation webcast please click here…

To view the Interim Results Presentation slide deck please click here…

10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.

Read more…

21 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its Scientific Advisory Board.

Read more…